Guard Therapeutics announces completion of data collection in Phase 2b POINTER study

Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing open-heart surgery.

“We are very pleased that data collection progressed according to plan during the summer, allowing the study to be completed ahead of schedule,” said Tobias Agervald, CEO of Guard Therapeutics. “With all data collected, we now look forward to the upcoming readout in the fourth quarter.”
 
A total of 170 patients were randomized and treated at 19 clinical sites across Europe and Canada. The purpose of the study is to evaluate the efficacy and safety of RMC-035 in preserving kidney function after surgery in patients at high risk of acute kidney injury – a common and serious complication of open-heart surgery.
 
Following completion of data collection, work is now underway to finalize all data, after which the study can be unblinded and the results analyzed. The overall results are expected to be available and communicated during the fourth quarter of 2025.

Datum 2025-09-11, kl 17:10
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!